Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has entered into a global licensing agreement with Germany-based Merck KGaA, granting Merck exclusive rights to its RenMice platform. The platform will be used to discover and develop human antibodies against unlimited drug targets, with Merck holding full rights to development, manufacturing, and commercialization of resulting candidates.
Agreement Details
Under the terms of the deal, Merck will pay Biocytogen undisclosed milestone payments tied to development and regulatory achievements. The agreement follows a period during which Merck evaluated the platform’s capabilities.
Biocytogen’s Capabilities
Biocytogen operates facilities in China (Haimen and Shanghai), the US (Boston), and Germany (Heidelberg). The company’s proprietary RenMice platform (RenMab and RenLite Mice) supports monoclonal and bispecific antibody development. Additionally, Biocytogen offers an in vivo drug efficacy screening platform and has robust clinical development capabilities, covering the entire drug development process.
Pipeline and Collaborations
Biocytogen is advancing Project Integrum and has entered into 24 drug development partnerships. Its pipeline includes 12 core products, with two undergoing global Phase II trials and two in Phase I studies.-Fineline Info & Tech
